PMID- 12745659
OWN - NLM
STAT- MEDLINE
DCOM- 20030717
LR  - 20061115
IS  - 1024-5332 (Print)
IS  - 1024-5332 (Linking)
VI  - 8
IP  - 2
DP  - 2003 Apr
TI  - Dendritic cell-based immunotherapy for the treatment of hematological 
      malignancies.
PG  - 97-104
AB  - Dendritic cells (DCs) are professional antigen-presenting cells and are 
      frequently used in current immunotherapy protocols. The administration of DCs 
      loaded with tumor-associated proteins or peptides results in the induction of 
      immune responses against different types of malignant cells. Methods for 
      large-scale generation of DCs in a sufficient quality and quantity have permitted 
      their use in clinical experiments. DC-based vaccines have already shown promise 
      in follicular non-Hodgkin's lymphoma, and to some extent, in other hematological 
      malignancies. Several strategies have been developed to boost their potency as a 
      new and relatively non-toxic treatment modality. Our review focuses on clinical 
      trials using DCs in the treatment of hematologic malignancies and on recent 
      studies of the immunophenotype, development, and maturation of DCs may have an 
      important impact on designing DC-based antitumor vaccines.
FAU - Buchler, Tomas
AU  - Buchler T
AD  - Laboratory of Experimental Hematology and Immunotherapy, Department of Clinical 
      Hematology, Masaryk University Hospital, Brno, Czech Republic. tbuchler@fnbrno.cz
FAU - Michalek, Jaroslav
AU  - Michalek J
FAU - Kovarova, Lucie
AU  - Kovarova L
FAU - Musilova, Romana
AU  - Musilova R
FAU - Hajek, Roman
AU  - Hajek R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/*immunology
MH  - Apoptosis
MH  - Cancer Vaccines/*therapeutic use
MH  - Dendritic Cells/classification/immunology/*transplantation
MH  - Forecasting
MH  - Hematologic Neoplasms/immunology/*therapy
MH  - Hodgkin Disease/immunology/therapy
MH  - Humans
MH  - Immunophenotyping
MH  - Immunotherapy/*methods
MH  - Leukemia/therapy
MH  - Lymphocyte Activation
MH  - Lymphoma, Non-Hodgkin/immunology/therapy
MH  - Multiple Myeloma/therapy
MH  - T-Lymphocyte Subsets/immunology
MH  - Vaccination
RF  - 86
EDAT- 2003/05/15 05:00
MHDA- 2003/07/18 05:00
CRDT- 2003/05/15 05:00
PHST- 2003/05/15 05:00 [pubmed]
PHST- 2003/07/18 05:00 [medline]
PHST- 2003/05/15 05:00 [entrez]
AID - Q4QDDKHA58XWCLW7 [pii]
AID - 10.1080/1024533031000084204 [doi]
PST - ppublish
SO  - Hematology. 2003 Apr;8(2):97-104. doi: 10.1080/1024533031000084204.